Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $120 | $121 | $114 | $148 |
| % Growth | -0.7% | 6.1% | -23% | – |
| Cost of Goods Sold | $44 | $38 | $41 | $65 |
| Gross Profit | $76 | $83 | $73 | $83 |
| % Margin | 63.4% | 68.3% | 64.3% | 56.1% |
| R&D Expenses | $26 | $22 | $18 | $27 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $56 | $60 | $51 | $74 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$21 |
| Operating Expenses | $81 | $82 | $70 | $80 |
| Operating Income | -$5 | $1 | $4 | $3 |
| % Margin | -4.3% | 0.7% | 3.2% | 1.8% |
| Other Income/Exp. Net | $2 | $2 | $1 | -$0 |
| Pre-Tax Income | -$3 | $3 | $4 | $2 |
| Tax Expense | $6 | $7 | $2 | -$2 |
| Net Income | -$56 | -$83 | -$15 | $4 |
| % Margin | -47% | -68.4% | -13.1% | 2.8% |
| EPS | -3.83 | -5.64 | -1.02 | 0.29 |
| % Growth | 32.1% | -452.9% | -451.7% | – |
| EPS Diluted | -3.83 | -5.64 | -1.02 | 0.28 |
| Weighted Avg Shares Out | 15 | 15 | 15 | 14 |
| Weighted Avg Shares Out Dil | 15 | 15 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $2 | $1 | – |
| Interest Expense | – | $0 | $0 | – |
| Depreciation & Amortization | $8 | $14 | $14 | $14 |
| EBITDA | $3 | $15 | $18 | -$4 |
| % Margin | 2.5% | 12.5% | 16% | -2.8% |